Eli Lilly said it’s cutting prices on its most prescribed insulin by 70% and expanding a program to cap out-of-pocket costs for the medication at $35 per month at participating pharmacies, a move that could make it more accessible to Americans with diabetes.
The list price for non-branded Insulin Lispro Injection will be cut to $25 a vial in May, while some Humalog and Humulin doses will be slashed 70% in the fourth quarter. Newly-launched Rezvoglar will sell at a 78% discount to its so-called biosimilar — Sanofi’s Lantus — starting in April, the company said in a statement Wednesday.
